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Abstract: The genetic diversity and frequent emergence of novel genetic variants of porcine re-
productive and respiratory syndrome virus type-2 (PRRSV) hinders control efforts, yet drivers of
macro-evolutionary patterns of PRRSV remain poorly documented. Utilizing a comprehensive
database of >20,000 orf5 sequences, our objective was to classify variants according to the phyloge-
netic structure of PRRSV co-circulating in the U.S., quantify evolutionary dynamics of sub-lineage
emergence, and describe potential antigenic differences among sub-lineages. We subdivided the most
prevalent lineage (Lineage 1, accounting for approximately 60% of available sequences) into eight
sub-lineages. Bayesian coalescent SkyGrid models were used to estimate each sub-lineage’s effective
population size over time. We show that a new sub-lineage emerged every 1 to 4 years and that
the time between emergence and peak population size was 4.5 years on average (range: 2–8 years).
A pattern of sequential dominance of different sub-lineages was identified, with a new dominant
sub-lineage replacing its predecessor approximately every 3 years. Consensus amino acid sequences
for each sub-lineage differed in key GP5 sites related to host immunity, suggesting that sub-lineage
turnover may be linked to immune-mediated competition. This has important implications for
understanding drivers of genetic diversity and emergence of new PRRSV variants in the U.S.
Keywords: porcine reproductive and respiratory syndrome virus; phylogenetic analysis; principal
component analyses; mutations; viral population dynamics; whole genome; multi-strain dynamics
1. Introduction
Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most
important pathogens affecting swine globally [1–4]. In the United States, the annual esti-
mated economic losses due to PRRS are approximately USD 664 million [5], with economic
losses stemming from reproductive failure, abortion, premature farrowing, increased rate
of stillborn piglets [6], pre-weaning mortality as extreme as 70% among piglets [7], and
losses in production parameters such as post-weaning mortality, daily gain, and feed
conversion [8,9]. Up to 40% of the U.S. breeding herd experience outbreaks annually [10],
which exemplifies the widespread impact of this virus in the U.S.
As demonstrated by the continued endemicity of PRRS in the U.S., efforts to control
PRRSV spread have had limited success and are further complicated by the emergence of
new genetic variants [11,12]. Current PRRSV vaccines display varying protection against
homologous and heterologous challenges [13–16], and the diversity of wild-type PRRSV
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variants makes it difficult to predict the nature of immunity elicited by naturally occurring
variants against heterologous challenges [17]. Although protection elicited by vaccination
or intentional pre-exposure of animals to PRRSV may help mitigate clinical disease impact,
current PRRS vaccines and pre-exposure procedures do not produce sterilizing immunity.
This may unintentionally create conditions for immune-driven viral adaptation. In addition,
recombination between different circulating strains has also been documented [18,19],
further illustrating potential risks for viral evolution.
PRRSV is divided into two major viral types—European (type-1) and North-American
(type-2) [1,20]. While each of the types is more prevalent on its respective continent, both
types can be found across North America, Europe, and Asia [1,20]. PRRSV type-2 viruses
are further categorized according to restriction fragment length polymorphisms (RFLP)
in the open reading frame 5 gene (orf5) portion of the viral genome [21,22]. RFLP typing
has recognized shortcomings, which include an inability to represent genetic relationships
between different RFLP types, the potential for distantly related viruses to share the same
RFLP type [23], and the instability of RFLP types over as few as 10 animal passages [24].
Partially due to these ambiguities in interpreting RFLP types, an alternative classification
system based upon phylogenetic lineages was proposed in 2010 [20,25]. This classification
system grouped PRRSV type-2 viruses into nine lineages based on phylogenetic relation-
ships in the orf5 region. The genetic distance between these lineages was approximately
10–17% based on nucleotide identity [25]. Lineages 1, 2, 5, 6, 7, 8, and 9 have been de-
tected in the U.S., with specific lineages more prevalent in certain parts of the country [25].
However these lineages have continued to diversify, and using a dataset from a single
U.S. region from years 2009–2017, at least three sub-lineages within Lineage 1 have been
documented, with sequential turnover in the dominant lineages through time [23]. In addi-
tion, the emergence of new sub-lineages can occur on time scales as short as two years (as
observed for the 1A sub-lineage associated with RFLP-type 1-7-4) [23], with rapid spread
of emerging sub-lineages driven by animal movements and local area spread [26,27].
Lineage 1 continues to be the most prevalent and diverse lineage within the U.S. swine
industry; consequently, an updated and expanded sub-lineage classification system is
needed to better track PRRSV Lineage 1 diversity in the U.S. and improve communica-
tion and coordination of control efforts. In addition, the macro-evolutionary dynamics of
PRRSV circulation in the U.S. remain poorly described at broader and more representative
geographic scales, and there is need to advance our understanding of how PRRSV variants
emerge and what processes underpin lineage turnover. Additionally, understanding the
potential role that host immunity has in shaping viral population dynamics is impor-
tant, given that PRRSV preventive and mitigation measures in the U.S. often involve the
pre-exposure of animals with either modified live vaccines or live virus inoculation. In
this paper, we used a comprehensive database of >20,000 orf5 sequences to investigate
phylogenetic sub-structure within Lineage 1 Type-2 PRRSV sequences in the U.S., describe
past disease dynamics through quantifying viral population sizes across time, and identify
antigenically relevant amino acid changes associated with each sub-lineage.
2. Materials and Methods
2.1. Source of Sequences
This study was conducted using 21,211 orf5 sequences from the University of Min-
nesota Veterinary Diagnostic Laboratory (UMN VDL). The UMN VDL receives samples for
diagnostic purposes from throughout the country and is perceived as one of the leading
reference VDLs for swine diseases in the U.S. Samples sent for diagnostics usually comprise
blood, tissue, or other clinical samples obtained from animals with clinical manifestation
compatible with a PRRSV infection, or from farms collecting samples as part of routine
monitoring. Diagnosis usually involves an RT-PCR test for the detection of PRRSV and, in
selected cases, Sanger sequencing of the orf5 region of the viral genome—approximately
10% of all PRRSV-positive tests executed at the UMN VDL are sequenced.
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At the UMN VDL, multiple samples can be submitted within a single case ID, which
usually represent different animals (sometimes pooled) from a single farm. Thus, more
than one sequence can be generated for a single case ID. Given that sequences associated
with a single farm at a single time point are pseudo-replicates (they more likely represent
a single introduction into the farm rather than the introduction of two distinct viruses
simultaneously), only the first sequence within each case ID was retained for our analysis
in situations where multiple sequences were associated with a single case ID. In addition,
sequences for which a complete date of collection was not available were also discarded
from the analysis.
2.2. Phylogenetic Classification Using Discriminant Analysis of Principal Components
We followed the same rationale for the classification of sequences into lineages as
previously published [23]. Briefly, a collection of 841 ORF5 gene sequences served as
“anchors” to classify the sequences of this study into one of the nine lineages previously
described [20,25]. Sequences were aligned to the anchors using the MUSCLE algorithm
in AliView [28]. The aligned data set was imported into Mega 10 [29], where the genetic
pairwise distance was calculated as a percentage nucleotide difference. Using Stata 15 [30],
each sequence was assigned to the lineage of the most closely related anchor.
To further refine the classification of lineage 1 sequences, we used a discriminant
analysis of principal components (DAPC) available via the package adegenet 2.0.0 [31] in
R [32]. This method was utilized to uncover the inherent structure present within the
Lineage 1 sequence dataset; sequences were clustered such that between-group differences
were maximized and within-group variation was minimized. Essentially, this is a principal
component analysis, which reduces the dimensionality of the sequence data set into
principal components, coupled with a discriminant analysis. We performed this analysis
with the unclassified Lineage 1 orf5 sequences from the UMN VDL alongside 75 Lineage
1 anchor sequences [23]. These anchor sequences, which were previously classified into
three sub-lineages (L1A-C), were used as guides to ensure our DAPC protocol was able
to adequately reconstruct the previously documented structure. We retained 70 principal
components, accounting for 80% of the genetic data variance, in the discriminant analysis
(Figure 1A). The optimal number of clusters in which to group sequences was defined as
the number of clusters that yielded the smallest Bayesian information criterion (BIC) in the
DAPC analysis while preserving the previously described sub-lineage structure.
The rate at which recombinant sequences were present in our data set was determined
by detecting recombinants on a subset of data (due to limited bioinformatics available to
handle a data set as extensive as ours), and we found that the frequency of orf5 recombinants
was ~0.1% (which would amount to fewer than 20 recombinants in all our sequences).
The identification of recombinants in the entire data set was precluded due to inherent
limitations of bioinformatics for data sets this large. Although recombinants may be present
in the dataset, the random sub-sampling of sequences for further analysis diminishes the
impact they may have had, since the likelihood that recombinants were present in sub-
sampled runs of the further analyses is reduced.
2.3. Effective Population Size through Time
The temporal signal in phylogenetic data sets of each sub-lineage was first investigated
using TempEst to confirm the appropriateness of the data for time-scaled phylogenetic tree
reconstruction [33]. We then used Bayesian SkyGrid coalescent models to estimate past
population dynamics through time [34]. Briefly, this approach estimates a sub-lineage’s
effective population size by evaluating the genetic diversity through time under an ide-
alized reproductive model [34]. In comparison to raw sequence counts, this approach is
less sensitive to undersampling (such as reduced sequence availability in earlier years),
and oversampling where many highly-similar sequences are obtained (such as in an
outbreak investigation), thus improving our ability to discern population-wide lineage
turnover through time. A relaxed uncorrelated lognormal (UCLN) molecular clock was
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used, with a flexible Bayesian SkyGrid plot (BSP) demographic model and a general-time
reversible model of nucleotide substitution with gamma-distributed rate variation among
sites (GTR+Γ), allowing for partitions into codons in any of three positions [35]. Models
were run with 200 million Markov chain Monte Carlo repetitions per run, sampling one
of each 1000 trees, which was sufficient to obtain a stable posterior distribution. These
analyses were implemented using BEAST (v1.10.4) on XSEDE on the CIPRES Cyberinfras-
tructure for Phylogenetic Research [36]. The steps above were replicated three times for
each PRRSV type-2 lineage and sub-lineage found in the data. Due to computational con-
straints, each replicate analysis was performed on a different set of 300 sequences of each
lineage/sub-lineage that were randomly selected from the total pool of sequences of each
lineage/sub-lineage. BEAST results of the three runs belonging to the same lineage/sub-
lineage were combined using LogCombiner [37]. The individual and combined BEAST
results were read into Tracer to evaluate model convergence and consistency between repli-
cates; the individual and combined model outputs were used to reconstruct SkyGrid plots
of the estimated viral population size through time [38]. Overall, individual and combined
BEAST runs of the same lineage/sub-lineage yielded similar results, and estimated viral
population sizes across time were consistent. Results were exported and plotted using
Stata [30].




Figure 1. Characteristics of the DPCA used to create sub-lineages within Lineage 1. (A) 80% variance 
was explained when retaining 70 principal components. (B) Grouping sequences into eight sub-
lineage clusters yielded the lowest BIC while still preserving previously documents sub-lineage 
structure. 
2.3. Effective Population Size through Time 
The temporal signal in phylogenetic data sets of each sub-lineage was first investi-
gated using TempEst to confirm the appropriateness of the data for time-scaled phyloge-
netic tree reconstruction [33]. We then used Bayesian SkyGrid coalescent models to esti-
mate past population dynamics through time [34]. Briefly, this approach estimates a sub-
lineage’s effective population size by evaluating the genetic diversity through time under 
an idealized reproductive model [34]. In comparison to raw sequence counts, this ap-
proach is less sensitive to undersampling (such as reduced sequence availability in earlier 
years), and oversampling where many highly-similar sequences are obtained (such as in 
an outbreak investigation), thus improving our ability to discern population-wide lineage 
turnover through time. A relaxed uncorrelated lognormal (UCLN) molecular clock was 
used, with a flexible Bayesian SkyGrid plot (BSP) demographic model and a general-time 
reversible model of nucleotide substitution with gamma-distributed rate variation among 
sites (GTR+Γ), allowing for partitions into codons in any of three positions [35]. Models 
were run with 200 million Markov chain Monte Carlo repetitions per run, sampling one 
of each 1000 trees, which was sufficient to obtain a stable posterior distribution. These 
analyses were implemented using BEAST (v1.10.4) on XSEDE on the CIPRES Cyberinfra-
structure for Phylogenetic Research [36]. The steps above were replicated three times for 
Figure 1. Characteristics of the DPCA used to create sub-lineages within Lineage 1. (A) 80%
variance was explained when retaining 70 principal components. (B) Grouping sequences into
eight sub-lineage clusters yielded the lowest BIC while still preserving previously documents sub-
lineage structure.
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Each sub-lineage’s year of emergence and year in which it reached peak population
size were determined based on the SkyGrid effective population size results. The year
of emergence was defined as the first of consecutive years in which the estimated viral
population size increased by a factor of two or more as compared to the previous year.
Although a given sub-lineage may sometimes be detected much earlier than this date, this
definition of emergence corresponded to periods of time in which rapid expansion in effec-
tive population sizes were visibly evident in SkyGrid plots, likely reflecting widespread
transmission of the sub-lineage. If such population expansions were observed in two non-
consecutive points of time, then both were flagged as (re-)emergences. A sub-lineage’s peak
was defined as the year with the highest estimated viral population size, or for sub-lineages
with several emergence and re-emergence events, the year with the highest estimated viral
population size between the two emergence events.
2.4. Clade-Prevalent Mutations
In order to better understand the significance of genetic differences between sub-
lineages, we extracted consensus amino acid sequences for each sub-lineage, with the
threshold of consensus set to 50%, 75%, and 90% of sequences within a sub-lineage possess-
ing a particular amino acid at a particular site. Consensus orf5 sequences were assembled
using Geneious Prime® [39]. The orf5 sequences of five commercially available vaccines in
the U.S. (Ingelvac PRRSV ATP–GenBank ID DQ988080.1, Ingelvac PRRSV MLV–GenBank
ID AF066183.4 (both from Boehringer Ingelheim), Fostera PRRSV–GenBank ID KP300938.1
from Zoetis, Prime Pac PRRSV RR–GenBank ID DQ779791.1 from Merck, and Prevacent
GenBank ID KU131568.1 from Elanco) were added to aid in comparisons between these
vaccines and the consensus sequence of each sub-lineage.
2.5. Comparison of Databases: UMN VDL & GenBank
To evaluate how representative the UMN VDL database is of the PRRSV type-2
diversity in the U.S., we downloaded all type-2 orf5 PRRSV sequences from GenBank
submitted from the U.S. and Canada up to 21 December 2020. GenBank sequences were
categorized as those that were available when the lineage classification of type-2 PRRS
was originally proposed (an analysis that included all available Genbank sequences up to
Jan 2009) [25], sequences contributed by our group in a prior publication [23], and other
GenBank sequences. GenBank sequences were classified into lineages/sub-lineages using
a set of anchors selected from each linage (L2–L9) and sub-lineage within L1 (Lineage
1A–1H). All sequences (GenBank and UMN VDL) were aligned using MAFFT [40]. A
maximum likelihood tree was built using the GTR model using IQ-TREE [41] and a time-
scaled tree was inferred using TreeTime [42] under a strict clock model. A phylogenetic tree
with the combined UMN VDL/GenBank data set was then illustrated using Nextstrain
2.0.0 [43].
3. Results
We obtained 21,211 orf5 PRRSV sequences from the UMN VDL representing samples
from 2001–2018. A total of 1005 duplicated sequences originating from the same case IDs
were excluded. Among the 20,206 unique case ID sequences, dates were not available
for 8083 sequences. Therefore, 12,123 sequences were carried over to the lineage/sub-
lineage assignment protocol. For comparison, by mid-February 2021, GenBank contained
approximately 26,500 PRRSV orf5 sequences from throughout the world (including both
type-1 and type-2 PRRSV). Approximately 59% of our sequences were classified as Lineage
1. Lineage 8 was the second most prevalent lineage, accounting for approximately 15% of
our sequences. The number of sequences classified in each lineage can be found in Figure 2.
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removing duplicates and sequences without a date.
Sequences belonging to Lineage 1 were further stratified into sub-lineages using
DAPC, which yielded 8 genetic groups within Lineage 1 denoted as sub-lineages 1A–1H.
An extensive set of refere ce sequences from the UMN VDL belonging to each li eage
and sub-lin age can be found on Ge Bank (accession numbers MZ303973–MZ304662).
The mean genetic distance within and between sub-lineages is shown on Table 1 (amino
acid distances are shown in Table S3). Overall, genetic distance between sub-lineages was
typically 13–15%, with the exception of the genetic distance between sub-lineage 1B and 1G,
which was approximately 6% (lineage 1G appeared to have emerged from 1B; Figure 3A).
The average genetic distance within sub-lineag s was <6%, with the exception of sub-
lineage 1D (Table 1). Whereas most sub-lineages formed well-resolved phylogenetic clades
(Figure 3A), sub-lineage 1D was a poorly resolved group containing sequences belonging to
two distinct clades, in addition to several poorly classified sequences (Figure 3A). Attempts
to increase the number of groups formed by DAPC to further subdivide this sub-lineage
resulted in misclassification of previously described 1A, 1B, and 1C seque ces. Therefore,
the largest clade within 1D was denoted as 1D-alpha. The remaining 1D sequences were
denoted as 1D-beta. 1D-beta was a particularly poorly resolved group containing the
smaller 1D clade and other 1D sequences not clearly belonging to any clade. Due to these
issues, sub-lineage 1D-beta was removed from further analysis.
RFLP types of all sequences were obtained, and the frequency of RFLP types within
each sub-lineage ca be found in Table S1, although we caution th t sub-lineages and
RFLPs are not simply different naming schemes capturing similar sub-structure within
PRRSV type-2. Overall, the most frequent RFLP type identified in the UMN VDL dataset
was 1-8-4, accounting for approximately 24% of the UMN VDL sequences. Approximately
73% of the 1-8-4 sequences belonged to sub-lineage 1F (mostly years 2004–2012), whereas
newer 1-8-4 sequences (mostly between 2013–2018) belonged to sub-lineage 1H. Within a
sub-lineage, RFLP frequency varied through time. For example, overall, the most frequent
RFLP type within sub-lineage 1A was 1-7-4 (approximately 60% of all 1A sequences), yet
1-7-4 frequency was 20% between 2001–2013 and 80% between 2014–2018.
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Table 1. Genetic distance (% nucleotide difference) within and between lineages and sub-lineages within Lineage 1 defined using the DPCA (including anchor sequences used as reference
for sub-lineages 1A, 1B, and 1C). Light gray cells show the average genetic distance of all sequences in each lineage and sub-lineage to commercially available PRRS vaccines.
Lineage
L1A L1B L1C L1D L1Dalpha L1Dbeta L1E L1F L1G L1H L2 L4 L5 L6 L7 L8 L9
n = 1095 n = 683 n = 1663 n = 469 n = 405 n = 64 n = 161 n = 1600 n = 1062 n = 519 n = 46 n = 2 n = 1116 n = 73 n = 18 n = 1831 n = 1469
L1A 4.0
L1B 10.1 4.0
L1C 13.4 14.5 6.0
L1D 12.6 14.4 14.2 12.0
L1Dalpha 12.7 14.6 14.7 12.0 12.0
L1Dbeta 11.8 13.6 11.4 12.2 13.0 7.0
L1E 14.9 15.7 16.2 14.6 14.6 14.6 5.0
L1F 11.7 13.7 12.5 13.6 13.9 11.4 15.5 6.0
L1G 11.0 6.2 15.0 15.2 15.4 14.0 16.3 14.0 5.0
L1H 14.2 15.9 14.7 14.7 15.3 11.4 17.1 13.1 15.9 5.0
L2 15.4 16.6 17.5 15.4 15.5 15.4 16.3 16.2 17.2 16.8 12.0
L4 14.9 15.6 16.7 15.3 15.3 15.3 17.1 15.8 16.7 17.3 16.6 16.0
L5 14.2 15.4 16.9 14.0 13.9 15.0 16.7 16.4 16.0 17.7 13.5 14.7 4.0
L6 17.3 18.5 19.4 16.6 16.5 17.5 18.8 18.1 18.9 17.8 17.0 17.4 13.4 6.0
L7 13.8 16.0 16.0 13.6 13.5 14.1 15.8 15.8 17.0 16.9 14.2 14.8 11.3 14.7 5.0
L8 15.3 16.0 17.1 14.2 14.0 15.3 16.4 16.6 17.2 17.5 14.7 15.7 12.0 15.1 12.4 6.0
L9 16.8 18.0 17.9 15.0 14.9 15.7 17.7 17.3 18.7 17.7 15.8 16.9 13.7 15.0 12.2 12.5 11.0
Prevacent-Elanco (L1) 12.4 15.0 12.8 13.2 14.1 7.5 15.7 12.5 15.1 12.2 16.8 16.6 15.7 19.0 14.5 16.9 16.8
Ingelvac PRRSV
MLV-BI (L5) 13.9 15.3 16.8 13.7 13.5 14.8 16.7 16.1 15.8 17.6 13.2 14.3 2.2 12.7 10.8 11.7 13.5
Prime Pac PRRSV
RR-Merck (L7) 13.8 16.0 16.1 13.3 13.2 13.9 16.5 15.7 17.0 16.5 13.8 14.7 10.6 14.1 3.2 11.7 11.4
Ingelvac PRRSV
ATP-BI (L8) 14.8 15.4 16.9 13.8 13.6 15.2 15.9 16.3 16.7 17.4 14.3 15.2 11.2 14.8 12.3 4.0 12.4
Fostera PRRSV-Zoetis
(L8) 14.6 15.9 16.2 12.6 12.4 14.3 15.4 15.9 16.7 17.1 13.0 14.1 9.8 12.4 8.8 7.3 9.3
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Sub-lineage 1C was the most prevalent sub-lineage identified overall, representing
approximately 22.8% of all Lineage 1 sequences (Figure 2). However, sub-lineage preva-
lence did not remain constant through time (Figure 3B), and periods in which specific
sub-lineages were more prevalent are clear. Sub-lineage 1C, for example, first appeared in
our data set in 2007 and was responsible for roughly 30–50% of all s quences identified
in any given year from 2010–2014. Sub-lineage 1F, on the other hand, was most prevalent
between circa 2002 until 2008, and has rarely been detected since 2014. Of note is the
sudden increase in the detection of certain sub-lineages, such as sub-lineage 1A. This group
was consistently detected across the early years of our data, but beginning in 2015, it
isplayed a marked increase in its occurrence, and subsequently has been responsible for
~30 to 40% of all detected sequences.
3.1. Sequential Dominance of Sub-Lineages through Time
Because sequencing effort has changed through time, the absolute frequency of se-
quences is challenging to interpret. Therefore, we quantified the expansion and contraction
of eac sub-lineage’s effective population siz using a SkyGrid analysis (Figure 4), which
was based on reconstruction of population trends based on genetic diversity in time-scaled
trees and was less sensitive to sampling effort. All sub-lineages displayed a sufficiently
strong temporal signal (correlation between genetic divergence and sampling time, r2, for
different sub-lineages ranged between 0.18 and 0.67) to be suitable for phylogenetic analy-
ses involving molecular clocks. The estimated viral substitution rates were similar across
sub-lineages, ranging from 6.6 × 10−3 to 1.3 × 10−2 substitutions/site/year (Table S2).
Figure 4 shows the SkyGrid plots of each sub-lineage overlaid to facilitate comparisons of
the effective population size of each sub-lineage through time; SkyGrid plots with 95% HPD
intervals are shown individually in Figure S1. Table 2 shows the year of (re-)emergence
and peak of each sub-lineage. On average, we observed the emergence or re-emergence of
a sub-lineage approximately every 1–4 years, and the time between sub-lineage emergence
and its peak estimated viral population size was approximately 4.5 years on average. Two
sub-lineages had more than one emergence and peak (L1A and L1E).
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Table 2. Year of emergence and peak of different sub-lineages. Sequences are ordered according to year of emergence. Cells
highlighted in gray mark sub-lineage that were the most prevalent in the population in the year of its peak. * Ongoing, as
our sequence data only extends to 2018.
Sublineage
Year of 1st Emergence Year of 2nd Emergence
Emergence Peak Difference betweenEmergence and Peak Emergence Peak
Difference between
Emergence and Peak
L1Dalpha <1990 2004 >15 - - -
L1F 2000 2005 5 - - -
L1B 2002 2008 6 - - -
L1A 2003 2011 8 2014 2016 2
L1C 2007 2011 4 - - -
L1G 2008 2014 6 - - -
L1E 2009 2014 5 2016 2018 * 2
L1H 2013 2017 * 4 - - -
This analysis demonstrated a clear turnover in the dominant sub-lineage (sub-lineage
with the largest population size) across years, with a different dominant sub-lineage
peaking every ~3 years (Table 2). The sub-lineage within Lineage 1 with the earliest date of
emergence was L1D-alpha, which was estimated to have emerged prior to 1990 and reached
its peak in 2004, though the sparsity of older sequences led to greater uncertainty about the
early dynamics of this sub-lineage. Prior to L1D, SkyGrid analyses of non-Lineage 1 PRRSV
revealed that Lineage 9 peaked in 2001 and Lineage 5 peaked in 1998, which was a historical
extension of the three-year cycle of lineage turnover observed for the sub-lineages within
Lineage 1 from 2004 to 2018. In the last three years of data (2015–2018), the sub-lineage
with the highest estimated viral population size was L1A, which peaked in 2016, although
L1H had the largest population size in 2018. A post hoc analysis of additional sequences
from 2019–2020 revealed that the relative frequency of L1H and L1A in VDL orf5 sequences
from 2019 and 2020 remained relatively stable, with ~25% of sequences in 2019 and ~37%
in 2020 belonging to L1H, and ~45% and ~38% belonging to L1A.
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3.2. Clade-Prevalent Mutations
The 50% consensus amino acids sequences of each sub-lineage’s ectodomains (amino
acid positions 27–61) are shown in Figure 5, and the 75% and 95% consensus sequences
for the whole ORF5 are shown in Supplementary Figure 2. Fewer amino acids reached the
consensus level as the threshold was increased; thus, the 75% and 95% consensus sequences
revealed highly conserved sites, whereas the 50% consensus revealed substitution patterns
that differentiated sub-lineages for the majority of sequences (Supplementary Figure S2).
Within the hypervariable regions, for example, we observed many differences in the amino
acids coded for at N-glycosylation sites (sites 32–34) or neutralizing epitopes (mainly in
sites 58–59). When the dominant sub-lineages were ordered by the year of emergence
to approximate population immunity potentially present immediately prior to each sub-
lineage’s emergence (Figure 5), there was no instance in which consecutively emerging
sub-lineages shared the same consensus pattern in positions 32–34 and 58–59 (although
in the latter case, the consensuses at 50% prevalence within each sub-lineage were not
always defined).
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4. Discussion
Here, we delineate sub-lineage structure and macro-evolutionary dynamics within
PRRSV Lineage 1 detected in the U.S. from 2001 to 2018. By applying a genetic clustering
algorithm to more than 7000 orf5 PRRSV Lineage 1 sequences, we found that the best
delineation of genetic diversity with Lineage 1 was achieved by grouping sequences into
eight sub-lineages. While whole genome sequencing (WGS) data would unveil a broader
perspective on PRRSV evolution, recent data has shown that sequences grouped together
as sub-lineages in orf5 phylogenies largely remain grouped by WGS [48], suggesting that
orf5-based lineage classification does reveal groups of viruses with shared ancestry. Here,
we show that each sub-lineage emerged and circulated in different periods through time,
showing a pattern of sequential turnover in the dominant sub-lineage. PRRSV is character-
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ized by a rapid rate of evolution, which represents a major obstacle for its control [49], since
genetic changes may affect virus neutralization [50,51]. An examination of common amino
acids within each sequential sub-lineage revealed differences at key amino acid sites (sites
33–34) that others have shown to be under positive selection pressure [23,45,46], and have
been shown experimentally to be linked to immune escape [52]. While the observational
nature of our data makes causality of sub-lineage emergence difficult to assess, the findings
of this study support hypothesis generation on processes that lead to the observed turnover
in sub-lineages through time. Taken together, our results support the idea that PRRSV
evolution and continued endemicity in the U.S. is characterized by multi-strain dynamics
driven at least partly by immune-mediated interactions [23,53].
While antigenic differences and the extent of immunological cross-protection among
sub-lineages described here has not been directly assessed, orf5 encodes for the major
envelope glycoprotein (GP5) that plays a key role in inducing virus neutralizing antibod-
ies, and particular amino acids encoded by ORF5 mediate the viruses susceptibility to
neutralization by the immune system [49,50,54,55]. Our results suggest that antigenic
differences may be captured to some extent by phylogenetic classification based on orf5,
though we acknowledge that whole-genome sequence data would likely reveal additional
antigenic differences in genomic regions outside of orf5 that play a role in immunity [49].
Within orf5, amino acid differences between sub-lineages (Figure 5) occur at sites that are
known to be involved with viral recognition or with immune response by the swine host,
such as hypervariable regions 1 and 2 (spanning between amino acid positions 32–39 and
57–61 [56–58]). Research suggests that these hypervariable regions evolve under positive
selection pressure [23,44–46] and contain several variable N-glycosylated sites [45,46] that
play an important role in host immune evasion [52,59,60]. However, differences in the
amino acids in other portions of the GP5 protein were also present; e.g., the unique amino
acids valine, threonine, and serine in the non-neutralizing epitope (amino acid positions
27–30) [61], which were more prevalent in L1D-alpha, L1G, and L1E, respectively. These re-
sults are important because they lend greater strength to the hypothesis that viral infections
by different sub-lineages within Lineage 1 may yield different immunological responses
in the animal, which could contribute to co-circulation of multiple PRRSV strains and the
antigenic fitness of newly emerging variants in a given region, system, or farm.
The alternating pattern of the presence of N-glycosylation at sites 33–34 across sequen-
tially emerging sub-lineages suggests that viruses that are antigenically distinct from the
previous dominant sub-lineage may have a fitness advantage [45,46], and thus are able
to successfully emerge against an immune backdrop shaped by its predecessor. While
whole-genome sequence data is needed to resolve this picture, our observations suggests
that there may be immunological differences between the ORF5-based lineage/sub-lineage
that may help explain the emergence/re-emergence of PRRSV lineages identified in the
U.S. Whole-genome sequencing data combined with further investigations examining how
point mutations affect protein secondary structure, protein folding, and post-translational
modifications may further help clarify the potential of such mutations in altering virus
recognition by the host immunological system.
To overcome limitations in inferring temporal patterns from raw numbers of sequences
identified through time, we described past viral population dynamics using a Bayesian
coalescent analysis that allowed us to better refine years of emergence and peak of each
sub-lineage, even permitting for the estimation of the average number of years that elapsed
between each sub-lineage’s emergence and peak. This approach allows us to minimize
potential biases in estimating the viral population size that would emerge if based purely
on raw frequencies. For example, if an extensive PRRSV outbreak investigation results in
the generation of many sequences, the inclusion of numerous closely related sequences
contributes relatively little additional genetic diversity to the data set, and thus has a
minimal impact on estimation of effective population sizes. Similarly, effective population
size estimates are robust to the sparsity of sequence data early in the study period, as long
as sampling was reasonably representative.
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Systematic biases in sampling could result in some phylogenetic clades being unde-
tected. In order to evaluate the representativeness of the UMN VDL database, we obtained
all type-2 orf5 PRRSV sequences from GenBank submitted from the U.S. and Canada, and
built a phylogenetic tree with the combined UMN VDL/GenBank dataset using Nextstrain
(Figure 6) [43]. All major clades found in GenBank were also found in the UMN VDL data,
particularly within Lineage 1. Thus, we believe that the sub-lineages within Lineage 1
described here are representative of the current diversity within Lineage 1 present in the
U.S. While the UMN VDL does provide sequencing services for clients across the U.S., its
location in the Midwest corn belt makes it particularly useful as a source of data for PRRSV
diversity, given that large numbers of pigs from throughout the U.S. and Canada are moved
into this region for finishing, and thus viruses circulating elsewhere in the U.S. are very
likely to be transported into the Midwest [25]. That being said, spatial heterogeneities
in the occurrence of sub-lineages likely exist, given that intensive swine production is
concentrated in certain parts of the country. This is apparent from our prior work, in which
we only identified three sub-lineages within a single U.S. production region between 2009
and 2017 [23], while this paper demonstrates that additional distinct sub-lineages circulated
in other parts of the country. It is also important to note that the proposed sub-lineages
were based on data from the U.S. only, and thus reflect phylogenetic structure present
within the U.S. and perhaps Canada (due to the connectivity of the two countries’ swine
industry), and are not meant to encompass diversity on other continents. Sub-lineages
(and past population dynamics) found on other continents are expected to be distinct from
those documented here [62–64].
Vaccines 2021, 9, x FOR PEER REVIEW 12 of 18 
 
 
Bayesian coalescent analysis that allowed us to better refine years of emergence and peak 
of each sub-lineage, even permitting for the estimation of the average number of years 
that elapsed between each sub-lineage’s emergence and peak. This approach allows us to 
minimize potential biases in estimating the viral population size that would emerge if 
based purely on raw frequencies. For example, if an extensive PRRSV outbreak investiga-
tion results in the generation of many sequences, the inclusion of numerous closely related 
sequences contributes relatively little additional genetic diversity to the data set, and thus 
has a minimal impact on estimation of effective population sizes. Similarly, effective pop-
ulation size estimates are robust to the sparsity of sequence data early in the study period, 
as long as sampling was reasonably representative. 
Systematic biases in sampling could result in some phylogenetic clades being unde-
tected. In order to evaluate the representativeness of the UMN VDL database, we obtained 
all type-2 orf5 PRRSV sequences from GenBank submitted from the U.S. and Canada, and 
built a phylogenetic tree with the combined UMN VDL/GenBank dataset using Nextstrain 
(Figure 6) [43]. All major clades found in GenBank were also found in the UMN VDL data, 
particularly within Lineage 1. Thus, we believe that the sub-lineages within Lineage 1 de-
scribed here are representative of the current diversity within Lineage 1 present in the 
U.S. While the UMN DL do  provide seq encing services for clie ts across the U.S., its 
location in the Midwest corn belt makes it particularly useful as a source of data for PRRSV 
diversity, given that large numbers of pigs from throughout the U.S. and Canada are 
moved into this gion for finishing, and thus viruses c rculating els where in the U.S. are 
very likely to be transported into the Midwest [25]. That being said, spatial heterogeneities 
in the occurrence of sub-lineages likely exist, given that intensive swine production is con-
centrated in certain part  of the co ntry. This is apparent from our p ior work, in which 
we only identified three sub-lineages within a single U.S. production region between 2009 
and 2017 [23], while this paper demonstrates that additional distinct sub-lineages circu-
lated in other parts of the cou try. It is also important to not  that h  proposed sub-line-
ages were based on data from the U.S. only, and thus reflect phylogenetic structure pre-
sent within the U.S. and perhaps Canada (due to the connectivity of the two countries’ 
swine indus ry), and are not me nt to encompass d versity on ther conti ents. Sub-line-
ages (and past population dynamics) found on other continents are expected to be distinct 
from those documented here [62–64]. 
 
Figure 6. (A) Nextstrain tree illustrating sequences from the UMN VDL and from GenBank according to its source, and 
(B) according to its lineage/sub-lineage. 
We identified that sub-lineages emerge and peak over time (Figure 4 and Table 2), 
with an average of 4.5 (ranging from 2 to 8) years elapsing between the emergence and 
Figure 6. (A) Nextstrain tree illustrating sequences from the UMN VDL and from GenBank according to its source, and
(B) according to its lineage/sub-lineage.
We identified that sub-lineages emerge and peak over time (Figure 4 and Table 2),
with an average of 4.5 (ranging from 2 to 8) years elapsing between the emergence and
peak, followed by a decline of the estimated viral population size of a sub-lineage. This
pattern was true for all sub-li eages except L1D-alph (early dynamics wer difficult to
quantify, as its period of emergence preceded sequence availability; Table 1) and L1F. The
consistency of this pattern for most sub-lineages within Lineage 1 suggests that there may
be something intrinsic to the U.S. swine industry structure that may define the upper limits
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of viral population size, possibly determined by dynamics of spread within and between
different swine-producing regions of the U.S.
Only two sub-lineages had a secondary re-emergence event following initial peaks
(Lineage 1A and 1E). From the raw frequencies, it is apparent that L1A’s second emergence
in 2014 was rapid, widespread, and more significant that its original emergence, whereas
L1E is of less interest, as it never became a dominant sub-lineage. L1A thus warrants
further discussion, since the two distinct emergence events represent separate clades,
further reinforcing the hypothesis that sub-variants within sub-lineages exist. Stratifying
L1A sequences into early and late clades, there were distinctions between the consensus
sequences in both the ectodomain (positions 32 and 34; Figure 5) and at position 121
(Figure S2). These clades emerged in different moments in time, at which the immunological
landscape was likely different. The first emergence of L1A occurred circa 2003, when the
most prevalent sub-lineage within Lineage 1 was L1D-alpha, followed by L1F and when
Lineage 9 sequences were also circulating more intensely (data not shown); while the
second emergence occurred in 2014, after a very complex turnover of sub-lineages within
Lineage 1 had occurred in the previous years (Figure 4), and shortly after a drastic increase
in the use of a modified live vaccine (belonging to Lineage 5) across the industry. It
is possible that the different immunological landscapes shaped evolutionary pressures
such that it favored the “re-emergence” of a slightly different L1A clade. Variants within
other sub-lineages may also have distinct immunological profiles that allow them to re-
circulate despite being of the same sub-lineage, thus population immune dynamics among
variants likely occur within as well as between sub-lineages, as exemplified by L1A. The
distinction between L1A’s two emergence events is also captured by examining the RFLP-
types associated with each clade: from 2001 to 2013, 49.5% and 19.0% of the L1A sequences
were classified as RFLP types 1-4-4 and 1-7-4, respectively. Between 2014 and 2018, this
frequency changed to 6.3% and 78.9%, respectively. While it is tempting to draw direct
parallels between sub-lineages and RFLP types, the relationship between both is more
complex than simply a different naming scheme. Thus, the exact frequency of RFLP within
each sub-lineage can change depending on when the data being referred to was collected.
Our paper further supports previous studies [23,25,65] that the phylogenetic classifi-
cation of PRRSV using orf5 provides more accurate evolutionary insights into the genetic
diversity of PRRSV than the current industry standard of RFLP-typing. Although phylo-
genetic classification may not discriminate among closely related variants, lineage/sub-
lineage classification minimizes ambiguities that occur when typing PRRSV using RFLP;
for example, the potential for distantly related virus (e.g., of different lineages) to have the
same RFLP pattern. It also diminishes the issue originating from the intrinsic instability
associated with RFLP typing, which has been shown to yield different RFLP patterns of
a PRRSV virus in as few as 10 animal passages [24]. While sub-lineages may not have
sufficient resolution to be used as sole definition for localized outbreaks [66], they may
be helpful in avoiding RFLP-based case definitions that group together viruses that are
not phylogenetically related, as well as in elucidating the potential evolutionary origin of
novel variants. This may help reduce noise when conducting outbreak investigations and
perhaps provide more meaningful answers to the industry.
Further investigation into how well sub-lineages defined by using orf5 carry over to
phylogenies based on whole-genome sequencing is warranted. While sequences grouped
in the same sub-lineages defined here largely remain grouped together in the same clades
in WGS [48], it is less clear whether ancestral relationships between sub-lineages will be
preserved in all cases. In addition, specific mutations and viral subpopulations may only
be detectable using whole-genome sequencing [67]. However, adoption of whole-genome
sequencing in the industry must become routine for this information to be of practical use,
and there is concern that WGS is more likely to be preferentially performed for selected
viruses, based on (for example) unusual clinical presentation. The historical availability
of orf5 sequences must not be understated, and such large-scale data sets provide unique
opportunities to understand the natural history of the virus, despite being intrinsically
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limited to orf5. Epidemiological and evolutionary studies that aim to reconstruct historical
trends and past epidemic patterns based upon available historical sequences are likely to be
restricted to orf5, at least for now, simply due to practical limitations in obtaining equivalent
whole-genome data. Still, other regions of the genome are likely to harbor important
immunological sites and provide useful additional insights into PRRSV phylogeny macro-
evolution, and that important immunological sites may be present elsewhere other than
orf5 remains.
Besides lacking a whole-genome perspective, a limitation of our amino acid consensus
approach is that it glosses over geographical or temporal variation within a given sub-
lineage, and as such, we may be underestimating differences between variants. Despite
that, we were still able to detect differences in immunologically relevant sites, and the
sub-lineage classification here at least partially captures potential antigenic substructure
that seems to exist within Lineage 1. Another limitation of our work is the proportion of
sequences that were unable to be used on our analysis (40%, Table 1) due to the inability to
associate a date with the sequence. This high proportion of losses may have potentially
introduced biases if the distribution of these loses in time is not random. However, we
believe that this loss was random, since it originated mostly from lack of information at
sample submission.
Last, studies investigating variability in cross-neutralization among sub-lineages
would shed light on processes driving sub-lineage emergence and multi-strain dynamics
documented herein, and may provide important insight into selection of appropriate
vaccines or inoculums that provide the best immunological protection. Such studies
will provide important insights into viral evolution, emergence of new immune-escape
variants, and how to better immunize animals in order to minimize infection and maximize
production of healthy animals.
5. Conclusions
Here, we described the occurrence of PRRSV over 17 years in the U.S. using data
from one of the largest veterinary diagnostic laboratories in the country. We identified
the emergence and turnover of different lineages and sub-lineages in the commercial pig
population based on both sequence count data and estimated past viral population sizes
inferred from genetic diversity through time. The eight sub-lineages identified within
Lineage 1 differed in key amino acid sites of the GP5 that are thought to be involved
in the immune response to the virus. This further lends strength to the hypothesis that
immune-mediated competition or selection may drive the emergence of new sub-lineages
within Lineage 1 in the U.S. Additionally, the interactions in the immune response elicited
against these different sub-lineages warrants further investigation to provide insights into
herd protection via vaccination, disease control, and viral evolution.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/vaccines9060608/s1, Figure S1. Estimated population size (95% HPD) through time of the
combined runs of BEAST for each sub-lineage. Figure S2. Consensus amino acid for each position
in the ORF5 genome of the different sub-lineages within L1, according to prevalence within that
sub-lineage (50, 75, and 95%, respectively). Table S1. Absolute frequency of different RFLP types
in each sub-lineage within Lineage 1, sorted according to the most frequent RFLP found in the
entire dataset. Table S2. Substitution rate found on the different BEAST runs of samples for each
sub-lineage. Table S3. Percent amino acid difference between and within lineages and sub-lineages
within Lineage 1. Light gray cells report the average amino acid distance of all sequences in each
lineage and sub-lineage to commercially available PRRS vaccines.
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